Target Name: MIR188
NCBI ID: G406964
Review Report on MIR188 Target / Biomarker Content of Review Report on MIR188 Target / Biomarker
MIR188
Other Name(s): miR-188 | MIRN188 | hsa-miR-188-5p | microRNA 188 | MicroRNA 188 | hsa-miR-188-3p | hsa-mir-188

MIR188: A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 40% of the global cancer deaths due to this disease. The development of new treatments for cancer has become a major focus in the pharmaceutical industry, and researchers are constantly searching for new biomarkers and drug targets. In this article, we will explore one such drug target, MIR188, and its potential as a cancer treatment and biomarker.

MIR188: A miRNA Target

MIR188 is a microRNA (miRNA), a small non-coding RNA molecule, that is expressed in various tissues and cells of the body. It is a key regulator of gene expression and has been implicated in various cellular processes, including cell growth, apoptosis , and inflammation. In recent years, researchers have discovered that MIR188 is involved in the regulation of cancer cell survival and has become a promising drug target for cancer treatment.

Drug Targeting Strategies

Drug targeting strategies have become increasingly important in cancer treatment as traditional chemotherapy and radiation therapy have become less effective in controlling cancer growth. One approach to drug targeting is to target MIR188, which is known to be a drug-resistant gene expression factor. By inhibiting MIR188 function, researchers hope to reduce cancer cell survival and promote cell death.

MIR188 as a Biomarker

MIR188 has also been identified as a potential biomarker for cancer diagnosis and treatment. The expression of MIR188 has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. By using MIR188 as a biomarker, doctors can monitor the effectiveness of cancer treatments and make more informed decisions about patient care.

MIR188 as a Therapeutic Target

Research has also shown that MIR188 can be targeted with small molecules, such as inhibitors, to inhibit its function and reduce cancer cell survival. One such inhibitor, NEDD8, has been shown to inhibit MIR188-mediated signaling pathways and reduce cancer cell growth in cell culture and animal models of cancer.

Another approach to targeting MIR188 is to use RNA interference (RNAi) technology to knockdown MIR188 gene expression. RNAi is a technique that uses small interfering RNA (siRNA) to knockdown gene expression in living organisms. This technique has been shown to be effective in reducing cancer cell survival and inhibiting the growth of cancer cells in cell culture and animal models of cancer.

MIR188 as a Potential Drug

MIR188 has also been identified as a potential drug target for cancer treatment. By inhibiting MIR188 function, researchers hope to reduce cancer cell survival and promote cell death, leading to a more effective cancer treatment. One such inhibitor, KO-1317, has been shown to inhibit MIR188-mediated signaling pathways and reduce cancer cell growth in cell culture and animal models of cancer.

Conclusion

MIR188 is a promising drug target for cancer treatment due to its involvement in the regulation of cancer cell survival. By inhibiting MIR188 function, researchers hope to reduce cancer cell survival and promote cell death, leading to a more effective cancer treatment. Further research is needed to fully understand the potential of MIR188 as a drug target for cancer treatment.

Protein Name: MicroRNA 188

The "MIR188 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR188 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682